In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Media coverage can help biopharma executives connect with, inform and inspire the public. In this column, ...

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...

Drugs are being invented and manufactured right here in the U.S. by Americans, for Americans. So why doesn’t the industry ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...